feng-yu-shutterstock-com-1
Feng Yu / Shutterstock.com
28 October 2015Americas

PTAB grants IPR of Celgene patents after Kyle Bass challenge

The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board (PTAB) to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 September 2015   Biopharmaceutical company Celgene has reiterated its stance on the inter partes review petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision.
Big Pharma
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.
Americas
31 July 2019   In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review proceedings to a pre-American Invents Act patent isn’t unconstitutional.

More on this story

Americas
29 September 2015   Biopharmaceutical company Celgene has reiterated its stance on the inter partes review petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision.
Big Pharma
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.
Americas
31 July 2019   In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review proceedings to a pre-American Invents Act patent isn’t unconstitutional.

More on this story

Americas
29 September 2015   Biopharmaceutical company Celgene has reiterated its stance on the inter partes review petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision.
Big Pharma
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.
Americas
31 July 2019   In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review proceedings to a pre-American Invents Act patent isn’t unconstitutional.